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Abstract
Background: Eosinophilic cystitis is a rare inflammatory disorder characterized by eosinophilic infiltration of all
layers of the urinary bladder wall. Due to lack of consensus and potential for side effect from various therapeutic
options, treatment of the disease is often challenging.
Case presentation: A 64-year old woman with hypertensive nephropathy resulting in stage III chronic kidney
disease, obstructive sleep apnea, and obstructive lung disease presented with a 4 month history of dysuria,
urgency, frequency, and persistent hematuria. Based on eosinophilic infiltration on bladder wall biopsy in the
absence of any evidence of infection, malignancy, or immune disorder, she was diagnosed with eosinophilic cystitis.
Despite multiple medication regimens, her symptoms persisted, requiring high-dose prednisone with steroid-related
side effects. After four months, she was started on cyclosporine, which led to symptomatic improvement and
reduction in prednisone dosage. At that time, repeat urine cytology and cystoscopy did not reveal friable tissues or
eosinophiluria.
Conclusion: This case illustrates the utility of using cyclosporine to treat eosinophilic cystitis in adult patient with
multiple comorbid conditions.
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Background
Eosinophilic cystitis (EC) is a rare inflammatory disorder
characterized by eosinophilic infiltration of all layers of
the urinary bladder wall, muscle necrosis, and fibrosis of
the mucosa and muscularis propria [1]. Due to its rarity,
not much is known about EC, and most of the data is
derived from individual case reports and case series.
Typically, patients with EC present with increased urin-
ary frequency, nocturia, dysuria, hematuria, suprapubic
pain and urinary retention [1–3]. Though there is a
higher prevalence among adults, EC has been known to
affect all age groups [1]. It has been associated with a
number of other disorders, including chronic vesical in-
jury, bladder neoplasms, interstitial cystitis, recurrent
urinary tract infections, parasitic infections, atopic dis-
eases and chronic granulomatous disease [2, 4–6].
Biopsy is essential for the diagnosis of EC, since other
forms of cystitis may also be accompanied by eosinophi-
luria and cystoscopic changes that resemble EC [2, 3].
Despite multiple proposed systemic, surgical and intrave-
sical approaches, treatment for the condition is often frus-
trating due to the lack of consensus and high rate of
recurrence [1, 2, 7]. Among promising therapeutic agents,
cyclosporine, a cyclophilin inhibitor whose downstream
effects include reducing the serum levels of Interleukin-4
(IL-4), IL-5, and IL-13, has been used successfully as long-
term treatment, as documented in two pediatric cases re-
ports [5, 8]. We advance the medical literature by describ-
ing our experience of using cyclosporine in an adult
female with biopsy-proven EC.
Case presentation
A 64-year old female with chronic kidney disease stage
III secondary to longstanding hypertension, chronic ob-
structive pulmonary disease, and obstructive sleep apnea
presented for evaluation of dysuria, urgency, frequency,
and persistent hematuria for 4 months at the University
at Iowa Hospitals and Clinics in July 2014. The rest of
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the review of systems was unremarkable. She had no his-
tory of atopic disease, including allergic rhinitis, asthma,
and atopic dermatitis, eosinophilia, parasitic infections,
toxin or radiation exposures, or recent travel. Her medi-
cation list at initial appointment with immunology in-
cluded albuterol, ciclesonide and salmeterol inhalers as
well as theophylline XR 300 mg, solifnenacin 10 mg,
phenazopyridine 100 mg, hydrocodone-acetamenophen
5–325 mg, nebivolol 2.5 mg, omeprazole 20 mg, sucral-
fate 1000 mg and multivitamin oral tablets/capsule. Methe-
namine mandelate was recently stopped by an outside
urologist as it was thought to contribute to the symptoms.
She was treated with several courses of antibiotics for urin-
ary tract infections (UTIs) since the onset of symptoms.
Vital signs were stable and physical examination revealed
only mild suprapubic tenderness. Cystoscopy performed
prior to the visit in July 2014 showed multiple friable muco-
sal lesions without tumor, stone, or clot, which was consist-
ent with diffuse hemorrhagic cystitis. Her work up during
the visit showed pyuria with hematuria, elevated inflamma-
tory markers including erythrocyte sedimentation rate, C-
reactive protein and leukocytosis with neutrophilia but
no peripheral eosinophilia. She had elevated Interleukin-
2R (CD25) and Th2 cytokines (Interleukin-4, Interleukin-
5 and Interleukin-13) with elevated Immunoglobulin E
(see Table 1).
She had no serologic evidence of prevalent parasitic
infections in the area (Strongyloides and Toxocara) or
autoimmune disease. Cytology and culture from bladder
washings in July 2014 did not identify any tumor cells or
infection; biopsy of the bladder wall, which contained
sections of the muscularis propria, showed eosinophil-
rich inflammatory infiltrate (Figs. 1 and 2).
Gram- and acid-fast bacilli stains of the biopsy were
also negative. Given the lack of tumor or infection, she
was diagnosed with eosinophilic cystitis.
At first, she was given combination of oral hydroxyzine
30 mg three times daily, oral prednisone taper (40 mg,
30 mg 20 and 10 mg) with dose reduced every 5 days and
solifenactin without significant improvement in symptoms
and hematuria. Later, she was given a trial of 6 weekly
courses of intravesical methylprednisolone followed by oral
prednisone, addition of loratadine 10 mg daily and monte-
leukast 10 mg daily with partial improvement in her symp-
toms without resolution of hematuria. Symptoms and
hematuria would worsen if the dose of prednisone was re-
duced below 25 mg daily. Additionally, she developed sev-
eral side effects of chronic prednisone use, including
tremors, weight gain, depressed mood, visual changes, and
Table 1 Cytokine panel and IgE level for 65 year old patient
with eosinophilic cystitis
Tests Reference range Patient’s level
IgE 0–100 IU/mL 551
Soluble Interleukin-2 Receptor (CD25) ≤1033 pg/mL 1351
Interleukin-12 ≤6 pg/mL <5
Interferon-γ ≤5 pg/mL 12
Interleukin-4 ≤5 pg/mL 8
Interleukin-5 ≤5 pg/mL 7
Interleukin-10 ≤18 pg/mL 10
Interleukin-13 ≤5 pg/mL 232
Interleukin-1β ≤36 pg/mL 22
Interleukin-6 ≤5 pg/mL <5
Interleukin-8 ≤5 pg/mL <5
Tumor necrosis factor-α ≤22 pg/mL 36
Interleukin-2 ≤12 pg/mL 12
Fig. 1 Low resolution hematoxylin and eosin (H&E) staining of bladder
wall biopsy of the patient, showing abundant eosinophils in mucosa
and submucosa
Fig. 2 High resolution hematoxylin and eosin (H&E) staining of
bladder wall biopsy of the patient, showing abundant eosinophils in
submucosa
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a fragility fracture of the hip, which mandated significant
dose reduction and resulted in worsening of her symptoms.
Repeat cystoscopy in November 2014 showed areas of
friable tissue similar to July 2014; urodynamic study in
December 2014 showed small capacity bladder suggest-
ing fibrosis of bladder wall as a complication of EC
resulting in Grade 2 bilateral vesicoureteral reflux and
higher risk of recurrent UTIs. She was offered surgical
treatment options including suprapubic catheter, cystec-
tomy or urinary diversion for relief of symptoms which
she declined. After weighing the risks and benefits of dif-
ferent therapy options, oral cyclosporine (50 mg twice a
day) was added to her regimen for a steroid-sparing ef-
fect and decrease Th2 cytokine profile. Over the course
of three months, her prednisone dose was decreased to
7.5 mg daily, which helped to reduce her depression,
tremors, and weight gain. Her renal function, as well as
blood pressure, remained stable. Despite being on a po-
tent immunosuppressant, her renal function as well as
blood pressure remained stable and frequency of recur-
rent UTIs did not increase compared to July 2014. Due
to side effects of nausea and recurrence of tremors with
two weeks trial of increased dose of cyclosporine 75 mg
twice daily, further dose escalation of cyclosporine were
avoided. Repeat urine cytology in April 2015 did not
show any eosinophils or tumor cells. She had a repeat
cystoscopy after 6 months of cyclosporine use that did
not show any friable mucosa, therefore no biopsy was
done. Moreover, she relayed decreased urgency and fre-
quency, and resolution of her overt hematuria.
Discussion
To our knowledge, this is the first case to document cyclo-
sporine as treatment for EC in an adult patient with mul-
tiple comorbidities. Although cyclosporine did not reverse
the fibrosis of the bladder wall secondary to EC, it allowed
reduction in dose of oral steroids and lead to sustained sig-
nificant improvement in the patient’s symptoms without
major adverse effects. Serum cytokine profile was consist-
ent with Th2 polarization; however eosinophilia was absent
in the patient. This observation is in line with our current
knowledge of how cyclosporine works: as a cyclophilin in-
hibitor, it inhibits interleukin-2 gene transcription and thus
prevents T-cell proliferation and Th2 polarization. Even
though long term safety data about use of cyclosporine in
EC is not available, it has been well tolerated when used
for interstitial cystitis [9]. Further studies are needed to
evaluate the efficacy and safety of cyclosporine use for EC
in adult patients with multiple comorbid conditions.
Conclusion
This case report illustrates the clinical utility of using
cyclosporine to treat eosinophilic cystitis in adult patient
with multiple comorbid conditions.
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